Obesity is a risk factor for heart failure (HF) development but is associated with a lower incidence of mortality in HF patients. This obesity paradox may be confounded by unrecognized comorbidities, ...
Cachexia is a metabolic disorder characterised by muscle wasting, diminished response to anti-cancer treatments and poor quality of life. Our objective was to identify blood-based biomarkers of ...
Inflammatory marker levels and prediction of patient-reported symptoms in patients with advanced pancreatic cancer receiving gemcitabine-based chemotherapy. This is an ASCO Meeting Abstract from the ...
Primary prevention of venous thromboembolic events (VTE) in cancer patients: An American survey study This is an ASCO Meeting Abstract from the 2004 ASCO Annual Meeting. This abstract does not include ...
Cachexia causes extreme weight loss and muscle wasting. It is a symptom of various chronic conditions such as cancer, chronic renal failure, HIV, and multiple sclerosis. Cachexia predominantly affects ...
MONTVALE, N.J., May 27, 2026 (GLOBE NEWSWIRE) -- EOM Pharmaceutical Holdings, Inc. (OTC: IMUC) (“EOM”, the “Company”) an innovative clinical-stage biotechnology company focused on developing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results